Rizatriptan

Rizatriptan is a selective agonist of the serotonin 5-HT1B and 5-HT1D receptors and is classed among the triptans, the standard drugs for aborting migraine attacks. Chemically it is a substituted tryptamine, related in structure to the neurotransmitter serotonin, carrying a triazole ring on the indole framework ^[1]. Within its class it is regarded as one of the faster-acting and more effective oral options for stopping an attack ^[2].

The drug was patented in the early 1990s and introduced for medical use in 1998, having been developed by Merck. It is a prescription-only medicine that is now widely available in generic form and remains among the more commonly prescribed migraine treatments ^[1]. It is marketed under names such as Maxalt and, in an orally disintegrating version, Maxalt-MLT, with a dissolvable film formulation sold as Rizafilm ^[2].

Rizatriptan is indicated for the acute treatment of migraine attacks, with or without aura, in adults, and it is also used in adolescents. Comparative trials and reviews have found it to provide rapid freedom from pain and to perform favorably against several other triptans as well as older therapies ^[1]. A large network meta-analysis of acute migraine drugs ranked rizatriptan among the most effective oral options for achieving pain freedom, alongside eletriptan, sumatriptan, and zolmitriptan ^[4]. It sits within a broader menu of acute treatments that clinicians tailor to the severity and features of each patient's attacks ^[3].

Rizatriptan is taken by mouth, either as a conventional tablet, as an orally disintegrating tablet that dissolves on the tongue without water, or as a thin oral film. It is meant for use once an attack has started rather than on a regular schedule, and it does not reduce how often attacks occur ^[3].

Rizatriptan is prescription only, and because it constricts blood vessels it is not for everyone. It is contraindicated in people with coronary artery disease, prior heart attack or stroke, uncontrolled high blood pressure, and certain other vascular conditions, since the vasoconstriction could reduce blood flow to the heart or brain. Common side effects are chest or throat tightness, tingling, dizziness, drowsiness, and flushing; the chest tightness is usually benign but must be taken seriously in anyone with heart risk. It should not be combined with ergotamine drugs or another triptan within 24 hours, and caution is needed with drugs that raise serotonin because of a small serotonin syndrome risk. People taking propranolol need a lower dose since it raises rizatriptan levels.

The best characterized interaction is with propranolol. Rizatriptan is cleared largely by monoamine oxidase A, and propranolol inhibits that pathway; in healthy volunteers, propranolol raised rizatriptan AUC by about 67% and peak concentration by about 75%. The effect is specific to propranolol, since nadolol and metoprolol studied the same way did not alter rizatriptan pharmacokinetics at all.

The same mechanism makes MAO-A inhibitors a contraindicated pairing, including phenelzine, tranylcypromine, isocarboxazid, moclobemide and linezolid; exposure rises considerably more than with propranolol.

Ergotamine, dihydroergotamine, methysergide and other 5-HT1 agonists share rizatriptan's vasoconstrictor action, and using them close together compounds coronary and peripheral vasospasm.

SSRIs and SNRIs carry a serotonin syndrome warning alongside triptans, though the reported case rate is low and the strength of that association is still debated.

Checking a whole stack? Run it through interactions + stacks.

Rizatriptan was developed by Merck & Co. as a second-generation triptan, part of the wave of serotonin 5-HT1B/1D receptor agonists that followed the pioneering success of sumatriptan. It was engineered for rapid oral absorption and good bioavailability, giving it a relatively fast onset among the oral triptans. The United States Food and Drug Administration approved it in 1998 under the brand name Maxalt, and it was also offered as an orally disintegrating tablet, Maxalt-MLT, that dissolves on the tongue without water. Its clinical program established that it could relieve migraine pain and associated symptoms such as nausea and light sensitivity in a substantial share of patients. It has since become a generic and remains one of the more commonly prescribed triptans for the acute treatment of migraine attacks.

Rizatriptan enjoys a strong reputation as one of the faster-acting and more reliably effective oral triptans, a distinction supported by head-to-head analyses of the class. Patients often value its speed of relief and the convenience of the melt-in-the-mouth formulation, which is useful when nausea makes swallowing pills or drinking water unappealing. Because it targets the trigeminovascular mechanisms of an attack in progress, it can abort migraines that are already underway rather than merely dulling the pain. It does not prevent future attacks, and it shares the class cautions of the triptans, including a need for care in people with significant cardiovascular disease and a risk of medication-overuse headache with frequent use. For the many people whose migraines respond to it, however, it offers dependable, well-studied relief and a welcome return to normal function.